U.S. FDA Approves Pfizer’s RSV Vaccine ABRYSVO® for Adults …
Oct 22, 2024 · ABRYSVO now offers the broadest RSV vaccine indication for adults, which previously included those 60 years and older. Additionally, it remains the only RSV …
FDA Approves First Vaccine for Pregnant Individuals to Prevent …
FDA approves Abrysvo for immunization at 32 through 36 weeks gestational age of pregnancy to prevent lower respiratory tract disease (LRTD) and severe LRTD caused by respiratory …
RSV Vaccine Labeling Updated With Guillain-Barré Syndrome …
4 days ago · The prescribing information for Abrysvo ® (respiratory syncytial virus [RSV] vaccine) and Arexvy ® (RSV vaccine, adjuvanted) has been updated to include a new warning …
Pfizer Announces Top-Line Results of ABRYSVO® for RSV in ...
Aug 12, 2024 · Participants demonstrated RSV-A and RSV-B subgroup neutralizing responses non-inferior to the response seen in the Phase 3 (NCT05035212) RENOIR study of …
FDA Approves Abrysvo to Treat Adults 18 to 59 Years of Age at …
Oct 23, 2024 · Abrysvo is the first RSV vaccine approved for adults aged 18-49 at increased risk for RSV-LRTD due to chronic conditions. The vaccine targets the RSV fusion protein, a major …
FDA approves first RSV vaccine for at-risk adults younger than 50
Oct 28, 2024 · The U.S. Food and Drug Administration (FDA) has approved Abrysvo, a vaccine that protects against lung infections caused by the respiratory syncytial virus — commonly …
RSV Vaccine Abrysvo Approved for Use During Pregnancy to …
Aug 22, 2023 · The Food and Drug Administration (FDA) has approved Abrysvo ™ (respiratory syncytial virus vaccine) for active immunization of pregnant individuals at 32 through 36 weeks …
Pfizer Announces Top-Line Results of ABRYSVO® for RSV in ...
Aug 12, 2024 · First assessment from an RSV vaccine study in immunocompromised adults show ABRYSVO was well-tolerated and generated strong neutralizing responses after a single dose …
RSV Vaccines Will Carry Warning for Guillain-Barré Syndrome
3 days ago · Abrysvo was first approved on May 31, 2023, for prevention of lower respiratory tract disease (LRTD) associated with RSV in adults aged 60 years or more, and has since been …
FDA Requires Guillain-Barré Syndrome (GBS) Warning
Jan 7, 2025 · ISSUE: FDA has required and approved safety labeling changes to the Prescribing Information for Abrysvo (Respiratory Syncytial Virus Vaccine) manufactured by Pfizer Inc. and …